4.5 Article

Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs

期刊

JOURNAL OF RHEUMATOLOGY
卷 36, 期 10, 页码 2164-2170

出版社

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.081204

关键词

PATIENT COMPLIANCE; ANTIRHEUMATIC AGENTS; RHEUMATOID ARTHRITIS; DRUG THERAPY; HEALTH KNOWLEDGE; ATTITUDES; PRACTICE

资金

  1. Sint Maartenskliniek, Nijmegen. The Netherlands

向作者/读者索取更多资源

Objective. Nonadherence in patients with rheumatoid arthritis (RA) Using disease modifying antirheumatic drugs (DMARD) may result in unnecessarily high levels of disease activity and function loss. The aim of this descriptive study was to assess adherence rates with self-report measures in a large random population, and to identify potential risk factors for nonadherence. Methods. A randomly selected sample of 228 patients with RA using DMARD was invited for a standardised interview. For each medicine, the patients were asked about adherence, consumption and perceived (side) effects. After the interview, the patients received self-report questionnaires to assess adherence [Compliance Questionnaire on Rheumatology (CQR) and the Medication Adherence Scale (MARS)], coping, beliefs about medicines, satisfaction about medicine information, and physical functioning. Subsequently, associations between adherence and demographics, clinical characteristics, and patient attitudes were examined. Results. Depending on the instrument used, 68% (CQR) and 60% (MARS) of the patients were adherent to DMARD. Nonadherence was not associated with demographic and clinical characteristics, satisfaction about information, medication concerns, and coping styles. The disease duration, the number of perceived side-effects, and beliefs about the necessity of the medicine were weakly associated with adherence. Conclusion. In this large study with a random RA population, 32%-40% of the patients did not adhere to their DMARD prescription. As none of the possible risk factors was strongly related to adherence,, no general risk factor seems to be powerful enough as a possible screening tool or target for adherence-improving interventions. This implies that nonadherence barriers should be assessed on an individual basis. (First Release Sept 1 2009; J Rheumatol 2009:36:2164-70; doi: 10.3899/jrheum.081204)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据